Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesRapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
27.02 USD 1.06 ( 4.08%)
Last update at 2026-11-11T21:00:00Z
VOLUME
624893
Market Cap
2047.71M

Momentum Score

…

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
25.77
Low
27.10
High
52 Week Price Range
23.75
Low
52.93
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapeutic candidates; public information indicates a focus on advancing its drug candidates through clinical development. Long-term growth may be driven by positive clinical trial readouts, licensing or partnership deals and eventual regulatory approvals, which could support commercialization and revenue generation, making the company of interest to investors seeking exposure to early-stage biotech innovation.
Key risks include high clinical and regulatory risk, potential need for additional capital leading to dilution, limited operating history and market competition that could prevent commercial success.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
25.96
Dividend Yield
-
Revenue TTM
20.00M
Revenue Per Share
0.45
Gross Profit TTM
-21.88M
Debt / Equity
0.02
ROE
-39.96%
Net Debt
-41.16M
ROCE
-25.36%
Diluted EPS TTM
-2.95

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -111.48M -78.31M -34.78M -10.65M
Net income -111.48M -78.31M -34.79M -10.65M
Selling general administrative 30.31M 22.12M 8.18M 1.37M
Selling and marketing expenses - - 0.11M -
Gross profit -1.02M -0.84M -0.11M -0.01M
Reconciled depreciation 1.02M 0.84M 0.11M -
Ebit -125.10M -83.06M -36.18M -10.37M
Ebitda -124.08M -82.22M -36.07M -10.35M
Depreciation and amortization 1.02M 0.84M 0.11M 0.01M
Operating income -125.10M -83.06M -36.18M -10.37M
Other operating expenses 125.10M 83.06M 36.18M 10.37M
Interest expense - - 0.00M 0.28M
Tax provision - 0.00M 0.01M -
Interest income 13.62M 12.14M 2.53M -
Net interest income 13.62M 12.14M 2.53M -
Income tax expense - - 0.01M -
Total revenue 0.00M 0.00M 0.00M -
Total operating expenses 125.10M 83.06M 36.18M 10.35M
Cost of revenue 1.02M 0.84M 0.11M 0.01M
Total other income expense net 13.62M 4.75M 1.40M -0.28M
Net income from continuing ops -111.48M -78.31M -34.79M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 512.43M 314.93M 155.42M 31.60M
Other current assets 8.02M 4.52M 3.39M 0.11M
Total liab 27.78M 9.51M 181.06M 12.10M
Total stockholder equity 484.65M 305.43M -25.63M 19.50M
Other current liab 12.10M 6.08M 5.63M 0.21M
Common stock 0.05M 0.04M 0.00M 0.03M
Capital stock 0.05M 0.04M 0.00M 0.00M
Retained earnings -235.23M -123.75M -45.44M -10.65M
Other assets - - 0.00M -
Cash 52.65M 56.80M 70.17M 31.16M
Total current liabilities 19.05M 8.77M 8.80M 1.66M
Current deferred revenue - - -2.50M -
Net debt -41.16M -55.33M -68.02M -20.72M
Short term debt 2.75M 0.74M 0.67M -
Short long term debt total 11.48M 1.48M 2.15M 10.44M
Other stockholder equity 719.29M 429.66M 19.80M 0.56M
Total current assets 498.56M 309.80M 150.87M 31.27M
Short term investments 437.89M 248.47M 77.31M 0.00M
Accounts payable 4.19M 1.95M 2.50M 1.45M
Accumulated other comprehensive income 0.55M -0.52M 0.00M -0.03M
Non currrent assets other 0.98M 0.16M 0.55M -
Non current assets total 13.87M 5.13M 4.55M 0.34M
Capital lease obligations 11.48M 1.48M 2.15M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -186.86M -170.14M -78.86M -
Total cashflows from investing activities -187.47M -170.14M -78.86M -5.28M
Net borrowings - - 0.00M -
Total cash from financing activities 270.79M 221.62M 145.14M 39.69M
Net income -111.48M -78.31M -34.79M -10.65M
Change in cash -4.16M -13.34M 39.09M 31.16M
Begin period cash flow 56.91M 70.25M 31.16M -
End period cash flow 52.75M 56.91M 70.25M 31.16M
Total cash from operating activities -87.47M -64.83M -27.18M -3.24M
Issuance of capital stock 269.44M 221.62M 145.27M -
Depreciation 1.02M 0.84M 0.11M 0.02M
Other cashflows from investing activities -187.47M 3.21M - -5.00M
Sale purchase of stock -0.00M 0.00M -0.00M -
Other cashflows from financing activities 270.79M 63.92M 145.09M -5.28M
Capital expenditures 0.62M 2.40M 1.64M 0.28M
Change in working capital 3.50M -2.42M 2.65M 1.49M
Stock based compensation 18.86M 10.23M 3.52M 0.61M
Other non cash items 0.64M 4.82M 1.32M 5.30M
Free cash flow -88.09M -67.23M -28.82M -3.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
RAPP
Rapport Therapeutics, Inc. Common Stock		 1.06
4.08%		 27.02 - - 102.39 4.98 84.10
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38

Profile*

Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

99 High Street, Boston, MA, United States, 02110

857 321 8020

https://www.rapportrx.com

84

Name Title Year Born
Dr. Steven M. Paul M.D. Founder & Independent Chairman 1951
Mr. Abraham N. Ceesay M.B.A. CEO, President, Treasurer & Director 1978
Mr. Troy A. Ignelzi Chief Financial Officer 1968
Dr. Jeffrey Sevigny M.D. Chief Medical Officer 1970
Dr. David Bredt M.D., Ph.D. Founder & Chief Scientific Officer 1966
Ms. Cheryl Gault Chief Operating Officer 1980
Ms. Karina Chmielewski Chief Information Officer & Head of Operations NA
Ms. Julie DiCarlo Head of Communications & Investor Relations NA
Ms. Kathleen A. Wilkinson Chief People Officer 1972
Mr. Swamy Yeleswaram Ph.D. Chief Development Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…